Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. (trading symbol: THAR) on June 7, 2024. The report discloses the entry into a material definitive agreement to facilitate the sale of the company's common stock.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new securities offering agreement.
Material Changes
On June 7, 2024, the Company entered into an At the Market Offering Agreement (the "ATM Agreement") with Rodman & Renshaw LLC. Key terms include:
- Sales Agent: Rodman & Renshaw LLC.
- Commission: The Company will pay a commission of 3.0% of the aggregate gross proceeds from shares sold.
- Method: Shares may be sold via "at the market offerings" on the Nasdaq Stock Market LLC or other existing trading markets.
- Obligation: The Company is not obligated to sell any shares under this agreement.
- Registration: The offering is conducted pursuant to an effective shelf registration statement on Form S-3 (No. 333-270684) and a prospectus supplement dated June 7, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard terms of the ATM Agreement. The agreement includes customary indemnification and contribution rights provided to the Manager. The offering will terminate upon the termination of the ATM Agreement in accordance with its terms.
Investor Verification Checklist
- Verify the current share price and trading volume on Nasdaq to assess the potential impact of future "at the market" sales.
- Review the full text of the ATM Agreement (Exhibit 1.1) for specific price, time, or size limits the Company may impose.
- Monitor subsequent filings for actual sales activity and gross proceeds generated under this agreement.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to understand the necessity of this capital raise.